Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study

doi:10.1016/S2213-2600(22)00045-5

Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study

Research output: Contribution to journal › Article › peer-review

Original language	English
Pages (from-to)	566-572
Number of pages	7
Journal	The Lancet Respiratory Medicine
Volume	10
Issue number	6
DOIs	https://doi.org/10.1016/S2213-2600(22)00045-5
Publication status	Published - Jun 2022
Externally published	Yes

ASJC Scopus Subject Areas

Pulmonary and Respiratory Medicine

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S2213-2600(22)00045-5

Cite this

@article{42670479e586419b9c2667c19a1bdb45,

title = "Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license",

year = "2022",

month = jun,

doi = "10.1016/S2213-2600(22)00045-5",

language = "English",

volume = "10",

pages = "566--572",

journal = "The Lancet Respiratory Medicine",

issn = "2213-2600",

publisher = "Elsevier Limited",

number = "6",

}

TY - JOUR

T1 - Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT)

T2 - a case-control study

PY - 2022/6

Y1 - 2022/6

UR - http://www.scopus.com/inward/record.url?scp=85131701282&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85131701282&partnerID=8YFLogxK

U2 - 10.1016/S2213-2600(22)00045-5

DO - 10.1016/S2213-2600(22)00045-5

M3 - Article

C2 - 35227416

AN - SCOPUS:85131701282

SN - 2213-2600

VL - 10

SP - 566

EP - 572

JO - The Lancet Respiratory Medicine

JF - The Lancet Respiratory Medicine

IS - 6

ER -

Vaccine efficacy against severe COVID-19 in relation to delta variant (B.1.617.2) and time since second dose in patients in Scotland (REACT-SCOT): a case-control study

ASJC Scopus Subject Areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this